Mikaela Naylon Give Kids a Chance Act
Latest Action
Received in the Senate.
Official Summary
Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research. Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met;permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement;renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; andreauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research. The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra, a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)
GovScope Watchdog™
AI Government Intelligence™The Mikaela Naylon Give Kids a Chance Act of 2025 expands the Food and Drug Administration's (FDA) authority over research and regulation of rare pediatric diseases. It allows the FDA to enforce pediatric study requirements against drug sponsors who fail to demonstrate due diligence, modifies rules for molecularly targeted pediatric cancer drug investigations, and reauthorizes priority review vouchers for rare pediatric disease treatments through 2029. The bill also extends funding for pediatric research at the National Institutes of Health (NIH) through fiscal year 2027 and codifies the FDA's interpretation of orphan drug exclusivity, specifying that the seven-year exclusivity period applies only to the same drug for the same use or indication. This legislation is currently in process and has been received in the Senate.
This bill strengthens FDA oversight of pediatric drug research, supports funding for pediatric research, and clarifies orphan drug exclusivity rules, aiming to improve development and approval of treatments for rare pediatric diseases.
- Modifies pediatric cancer drug research rules to allow studies on new drugs combined with previously approved active ingredients under certain conditions.
- Authorizes the FDA to take enforcement actions against drug sponsors who fail to meet pediatric study requirements if due diligence is lacking.
- Reauthorizes priority review vouchers for sponsors of new rare pediatric disease products through September 30, 2029, and NIH pediatric research funding through FY2027.
- Provides statutory authority for the FDA's interpretation that orphan drug exclusivity applies only to the same drug and indication, aligning with FDA regulations but differing from a recent court ruling.
['Children with rare pediatric diseases', 'Drug sponsors and pharmaceutical companies developing pediatric treatments', 'Food and Drug Administration (FDA)', 'National Institutes of Health (NIH)', 'Researchers involved in pediatric disease studies']
["Enforcement authority granted to the FDA may require clear criteria to assess 'lack of due diligence' to ensure fair application.", 'Reauthorization of funding and priority review vouchers depends on future appropriations and regulatory implementation.', "The statutory codification of the FDA's orphan drug exclusivity interpretation may lead to legal or regulatory challenges given the conflicting court ruling.", 'Implementation complexity in modifying pediatric cancer drug investigation requirements could affect research timelines.']
The bill addresses ongoing legislative efforts to enhance pediatric drug development and regulatory oversight, reflecting priorities to improve treatments for rare pediatric diseases. It responds to existing FDA regulatory frameworks and recent judicial decisions, aiming to clarify and extend authorities related to pediatric research and orphan drug exclusivity. The bill has passed the House and is currently under consideration in the Senate.
High concern review — 3 hidden impact flags detected
GovScope reviewed 3 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Enhanced FDA enforcement authority may incentivize drug sponsors to prioritize pediatric studies, potentially accelerating pediatric drug development.', "Clarification of orphan drug exclusivity could influence pharmaceutical companies' strategies for drug approvals and market exclusivity claims.", 'Reauthorization of funding and vouchers may sustain or increase research activity in rare pediatric diseases, impacting long-term treatment availability.']
The bill expands FDA enforcement powers and codifies regulatory interpretations that have been legally contested, highlighting the importance of monitoring implementation and judicial responses. The reauthorization of funding and voucher programs depends on future appropriations, which may affect program continuity. Transparency in enforcement criteria and funding allocation will be critical for oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.